In summary, our results propose that ARID1A not only acts as a predictive biomarker in gliomas but also that its deletion, by undermining the stability of the SWI/SNF complex, may cause gliomas to exhibit more malignant features. This evidence concerns the gene ARID1A and central nervous system cancer.